- Home
- UHG vs RCEL Comparison
UHG vs RCEL Comparison
Compare UHG & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHG
- RCEL
- Stock Information
- Founded
- UHG 2004
- RCEL N/A
- Country
- UHG United States
- RCEL United States
- Employees
- UHG N/A
- RCEL N/A
- Industry
- UHG Homebuilding
- RCEL Medical/Dental Instruments
- Sector
- UHG Consumer Discretionary
- RCEL Health Care
- Exchange
- UHG Nasdaq
- RCEL Nasdaq
- Market Cap
- UHG 158.8M
- RCEL 136.7M
- IPO Year
- UHG N/A
- RCEL N/A
- Fundamental
- Price
- UHG $3.14
- RCEL $5.71
- Analyst Decision
- UHG
- RCEL Strong Buy
- Analyst Count
- UHG 0
- RCEL 4
- Target Price
- UHG N/A
- RCEL $16.50
- AVG Volume (30 Days)
- UHG 231.7K
- RCEL 314.8K
- Earning Date
- UHG 08-07-2025
- RCEL 08-07-2025
- Dividend Yield
- UHG N/A
- RCEL N/A
- EPS Growth
- UHG N/A
- RCEL N/A
- EPS
- UHG 0.76
- RCEL N/A
- Revenue
- UHG $449,877,017.00
- RCEL $71,661,000.00
- Revenue This Year
- UHG N/A
- RCEL $57.16
- Revenue Next Year
- UHG N/A
- RCEL $36.69
- P/E Ratio
- UHG $4.06
- RCEL N/A
- Revenue Growth
- UHG 5.24
- RCEL 41.35
- 52 Week Low
- UHG $1.60
- RCEL $4.71
- 52 Week High
- UHG $6.93
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- UHG 49.50
- RCEL 49.89
- Support Level
- UHG $2.71
- RCEL $5.13
- Resistance Level
- UHG $2.95
- RCEL $5.87
- Average True Range (ATR)
- UHG 0.33
- RCEL 0.31
- MACD
- UHG -0.07
- RCEL 0.14
- Stochastic Oscillator
- UHG 28.24
- RCEL 83.19
About UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.